Comparative Study of Incadronate and Elcatonin in Patients with Malignancy-Associated Hypercalcaemia

2002 ◽  
Vol 30 (3) ◽  
pp. 230-243 ◽  
Author(s):  
T Matsumoto ◽  
N Nagata ◽  
N Horikoshi ◽  
I Adachi ◽  
Y Ohashi ◽  
...  
Keyword(s):  
Comparative Study ◽  
Adverse Drug Reactions ◽  
Serum Calcium ◽  
Intravenous Infusion ◽  
Rapid Onset ◽  
Clinical Usefulness ◽  
Efficacy And Safety ◽  
Drug Reactions ◽  
Intramuscular Injections ◽  
Disturbance Of Consciousness

The clinical usefulness of incadronate was compared with elcatonin in 26 patients with malignancy-associated hypercalcaemia. Data from 21 and 24 patients could be used to assess efficacy and safety, respectively. Eleven patients were given a single 10-mg intravenous infusion of incadronate and 10 received twice-daily intramuscular injections of 40 IU of elcatonin for 7 consecutive days. After treatment, corrected serum calcium levels decreased significantly in both groups. The anti-hypercalcaemic effect of elcatonin was characterized by its rapid onset, with serum calcium levels reduced 1 day after administration. In contrast, the anti-hypercalcaemic effect of incadronate was more sustained but only became apparent a few days after infusion. Evaluation of symptoms revealed significantly greater improvement rates in the incadronate group compared with the elcatonin group. Adverse drug reactions were observed in three patients in the incadronate group, i.e. mild and transient fever in two cases and exacerbation of disturbance of consciousness in one case. These findings suggest that incadronate produces more marked and sustained hypocalcaemic effects than elcatonin, and that co-administration of these two drugs may yield both rapid and sustained control of malignancy-associated hypercalcaemia.

scholarly journals Efficacy and safety of selamectin of flea infestation in dags

2018 ◽  
Vol 53 (1) ◽  
pp. 78
Author(s):  
S. SOTIRAKI (Σ. ΣΩΤΗΡΑΚΗ) ◽  
C. HIMONAS (Χ. ΧΕΙΜΩΝΑΣ) ◽  
P. DEBOUCK ◽  
G. BITSAS (Γ. ΜΠΙΤΖΑΣ)
Keyword(s):  
Adverse Drug Reactions ◽  
Clinical Signs ◽  
Untreated Group ◽  
Field Conditions ◽  
Efficacy And Safety ◽  
Drug Reactions ◽  
Flea Infestation ◽  
Highly Effective ◽  
Monthly Dose ◽  
Adult Flea

The study was conducted at three dog shekers in Thessaloniki Greece, το confirm die efficacy and safety of selamectin aτ a minimum dosage of 6 mg/kg adminisτered topically as a monthly dose repeaτed three times in die treatment of natural i n f l a t i o n s of Ctenocephalides spp. Twenty (20) dogs, with confirmed naturally acquired flea inflations, were enrolled in die sttidy as primary patiems. All animals completed the study on day 90. Twenty-two in cornai dogs were also treated but not evaluated for efficacy (secondary patiems). There was no untreated group. Only one live adult flea was recovered on only one animal on study day 30, a reduction of die geomettical mean of 99.7 % (p < 0.0001) compared to the sτarτ of die study. Dead fleas were found on 3 animals aτ day 30 (1 or 2 per animal). No live or dead fleas were found on day 60 or on day 90. Ατ sttidy beginning on Day 0, seventy percem of sttidy animals had various clinical signs of flea inflation. These signs gradually decreased and by die end of die sttidy on day 90, only one animal remained widi a score of 1, indicating a low imensity in a single area of die body. All odier animals were free of clinical signs. No abnormal clinical signs or suspend adverse drug reactions were observed after treatment of die 20 primary or die 22 secondary patiems. The daτa collected confirm that under field conditions diree consecutive mondily doses of selamectin are highly effective and safe in die treatment and comrol of fleas in dogs.

Adverse drug reactions to dopamine agonists: A comparative study in the french pharmacovigilance database

2010 ◽  
Vol 25 (12) ◽  
pp. 1876-1880 ◽  
Author(s):  
Santiago Perez-Lloret ◽  
Emmanuelle Bondon-Guitton ◽  
Olivier Rascol ◽  
Jean-Louis Montastruc ◽  
Keyword(s):  
Comparative Study ◽  
Adverse Drug Reactions ◽  
Dopamine Agonists ◽  
Drug Reactions ◽  
Pharmacovigilance Database

scholarly journals Comparative evaluation of efficacy and safety of methotrexate either alone or in combination with hydroxychloroquine in patients suffering from rheumatoid arthritis

2017 ◽  
Vol 6 (8) ◽  
pp. 1996
Author(s):  
Amanjot Kaur ◽  
Shakti B. Dutta ◽  
Amandeep Singh ◽  
Amit Varma ◽  
Mirza A. Beg ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Combination Therapy ◽  
Adverse Drug Reactions ◽  
Positive Family History ◽  
Efficacy And Safety ◽  
Drug Reactions ◽  
Intergroup Comparison ◽  
The Mean ◽  
Group 2 ◽  
Group 1

Background: Rheumatoid arthritis (RA) a chronic autoimmune inflammatory disease and Methotrexate being widely used as monotherapy and in combination for the treatment of RA. Combination therapy provides additional or even more potentiating effects, therefore have been widely used. This study is aimed at comparing the efficacy and safety of Methotrexate either alone or in combination.Methods: This study was conducted for one year from 1st January to 31st December 2015. 52 patients diagnosed with RA were included in this study and were divided in two groups, Group-1 (n=29) patients received methotrexate (MTX) 7.5-15mg/week and Group-2 (n=23) patients received methotrexate 7.5mg once a week + Hydroxychloroquine (HCQ) 200mg twice daily. The patients were followed up for a period of 16 weeks. Statistical analysis was done by using graph pad insta and p value of <0.05 was considered significant.Results: A total of 52 patients were included in the study. The mean age of patients was 50.53±14.81 years. 43 (82.69%) patients were females and 9 (17.30%) were males. 23 (44.23%) patients had positive family history of the disease. The Rheumatoid factor was positive in 42 (80.70%) and anti-CCP was raised in 50 (96.15%) patients. The RAPID-3 and DAS-28 scores on intragroup comparison was highly significant (p <0.0001) and the intergroup comparison was significant (p <0.01) between baseline and 16 weeks in both the groups. The improvement in inflammatory marker CRP was highly significant on intragroup (p <0.0001) and intergroup (p<0.001) comparison between baseline and 16 weeks in both the groups. The mean changes in Vitamin-D3 between baseline and at 16 weeks were insignificant (p >0.05) in both the groups. Total of Adverse drug reactions reported were 42 (50.60%) in group-1 and 41 (49.40%) in group-2.Conclusions: The combination therapy was found to be more efficacious than MTX monotherapy in improving symptoms and quality of life. The adverse drug reactions were mild, more in combination therapy and none of the patients required withdrawal of treatment.

A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006

2011 ◽  
Vol 21 (3) ◽  
pp. 285-288 ◽  
Author(s):  
Agnès Sommet ◽  
Genevieve Durrieu ◽  
Maryse Lapeyre-Mestre ◽  
Jean-Louis Montastruc ◽  
Keyword(s):  
Comparative Study ◽  
Adverse Drug Reactions ◽  
Heat Waves ◽  
Drug Reactions

scholarly journals Charms & Harms: Noni

2010 ◽  
Vol 2 (3) ◽  
pp. 254
Author(s):  
Felicity Goodyear-Smith
Keyword(s):  
Adverse Drug Reactions ◽  
Health Professionals ◽  
Herbal Medicines ◽  
Efficacy And Safety ◽  
Drug Reactions ◽  
Pharmaceutical Quality ◽  
Wide Range ◽  
Suspected Adverse Drug Reactions

SUMMARY MESSAGE: Evidence for the efficacy of noni for the wide range of medicinal purposes for which it may be used is not available. Health professionals should be aware of the possibility of (undisclosed) use of noni and its use should be avoided, or at least used only with caution, in patients on warfarin. Suspected adverse drug reactions should be reported to CARM. As with all herbal medicines, different noni products vary in their pharmaceutical quality, and the implications of this for efficacy and safety should be considered.

Sign in / Sign up

Export Citation Format

Share Document